Yes, in the midst of a severe global surge in new cases and deaths, there are several genuinely good news items that we can pin our hopes on. Surely, you are aware of some of these, but I will attempt to put them in context. As of yesterday, from the start of pandemic to […]
Articles
The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently featured the phrase “for the duration” – as in great numbers of combat fatalities would continue to be reported for the duration, […]
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same. Happily, thinking about migraines will not give me COVID-19. But migraines are by no means a topic of no consequence, […]
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and former journalist Suzanne Sena that Money Morning brings in to pitch their “super vaccine” idea… which doesn’t mean anything about the stock, of […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
Today’s ad for our consideration and de-teasification is from Jeff Yastine for his Total Wealth Insider newsletter over at Banyan Hill — that’s one of their “entry level” newsletters ($79/year), and this time he’s promising that he’s got a $5 stock from New Jersey that’s going to knock our socks off. OK, fine, he didn’t […]
We get “rebate” and “refund” and “enrollment” check teasers all the time, it’s a popular way to give investors, especially inexperienced investors, the illusion that there’s some free way to get money that they don’t know about (which many people always suspect, anyway)… the story typically is that all you have to do is sign […]
Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
Today I decided to sit down for a while with a teaser ad from Dr. Mark Skousen’s Forecasts & Strategies ($50/year) — this letter is actually from his publisher, Roger Michalski, but it focuses on an idea of Skousen’s that he calls “American X”. So what is this secret “American X” company? It’s apparently got […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
No, these bits won’t be about Melania’s kidney ailment nor yet about what Meghan wore for The Wedding. I wish them both luck – they’ll need it!. However, there continue to be developments on the medical and health-care fronts that may matter to us a good deal more than the doings of those ladies. […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]
[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]
[ed. note: Michael Jorrin, who I call “Doc Gumshoe,” writes for us a couple times a month on health and medical issues — he is a longtime medical writer (not a doctor), he chooses his own topics, and his past articles can be found here.] Flub Number One is the puncture of the “female Viagra” […]
[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
February 27, 2015 /
Michael Jorrin, "Doc Gumshoe"
Celiac Disease and the Ubiquitous Gluten-Free Diet
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with our readers a couple times a month. He does not generally cover investing topics, but I find his discussions of broader health issues interesting and useful. Enjoy!] Doc Gumshoe would not be […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
[ed note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who writes non-investment articles about medicine and health topics for us once or twice a month. As with all of our guest contributors and columnists, he chooses his own topics and his words are his alone] […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own, and he has agreed to our trading restrictions.] Want to see something really cool? A hot video clip from a steamy biotech thriller? Watch this. Better yet, when you pull up the video viewing frame, […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
[Michael Jorrin, who we like to call “Doc Gumshoe”, is a medical writer who shares his thoughts with us once or twice a month. He does not usually recommend or discuss investments, and, as with all of our contributors, his words are his own and he chooses his own topics.] To start us off, three […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]
[Ed. Note: Dr. KSS, formerly knowns as karmaswimswami on our discussion threads, is here again to talk to the Irregulars about health and medicine and biotech investing ideas. As with all of our guest contributors, he has agreed to our trading restrictions and we have not reviewed, approved or screened his stocks or ideas, and […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
The Wealth Advisory is one of those “entry level” newsletters that pretty much all publishers put out — it costs less than a hundred bucks a year, and it gets you used to paying for financial analysis without feeling too much pain … sort of a gateway drug before you get pitched on the “hard […]
As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Fool is pushing NVX and AZN, with PFE in the mix...
I agree, anytime there is a cure, a secret, conspiracy, or a book for sale creates more caution. Greed is writing the ...
#Biotech Best turnaround M&A $ARQL 20X $MRK BO in 2yr $ARRY $2s Multiple setbacks ➡️ 20X $PFE BO in 3yr $ECYT...
How do you think recent regulation allowing US consumers to purchase Rx's from Canada will impact PFE and other pharmace...
Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...
FYI: Pfizer earnings were fine, but the guidance for 2019 earnings was lower than analyst estimates (thanks to the stron...
Who knows if any of what Shousen says is true but I'm in PFE just because it's a good company and pays a nice dividend. ...
Switzerland is divided in three main region where we speak French, German and italian (plus grischun) hence the swiss-it...
It's more likely PFE would buy out $AMRN by the end of 2019, and that, folks, would be 100% easy from current levels....
It is Italian but operates its partnerships out of Switzerland and has linked up with lots of drug firms besides PFE inc...
It is Italian but operates its partnerships out of Switzerland and has linked up with lots of drug firms besides PFE inc...
I'll stick to investing in my brother. He's worked for 3 companies that have been acquired by PFE. He stayed for awhil...
That’s one of Jimmy Mengel’s recent teases, most of it is a rehash of previous pitches but that new addition of the ...
$AKAO Just finished reading the whole transcript of the Conference Call which I would suggest others do, time permitting...
Kiplinger makes a case for Pfizer (PFE) in your retirement account. http://www.kiplinger.com/slideshow/investing/T052-S...
For those that hold Pfizer (PFE) a good read. http://marketrealist.com/2016/11/pfizers-valuation-compared-to-peers/ ...
Pfizer (PFE) launching first mAb copycat at a small discount. http://endpts.com/pfizer-launches-first-us-mab-biosimil...
Joe, just wanted to note a couple of basics (and forgive me if you already know these): Do not use stock price as an in...
Incyte $INCY looks like a worthy alluring takeover candidate here to me. I suspect it's on a shopping list at both Aller...
Pfizer (PFE) blocking its drugs for lethal injections. https://www.yahoo.com/news/pfizer-says-blocking-drugs-lethal-i...
Pfizer (PFE) receives a large injection worth of calls. http://www.bottarelliresearch.com/trades/2016/01/28/pfizer-rece...
Pfizer (PFE) receives a large injection worth of calls. http://www.bottarelliresearch.com/trades/2016/01/28/pfizer-rece...
Pfizer (PFE) with 5 buy ratings in December. http://www.marketbeat.com/stocks/NYSE/PFE/ Cheers,Glenn...
Pfizer (PFE) mentioned being dirt cheap in overbought market. http://investorplace.com/2015/11/6-dirt-cheap-stocks-to-b...
Good news for Pfizer (PFE) today. http://fda.einnews.com/article/292317732/CSbRUhc0UqlsuELq Cheers,Glenn...
Pfizer (PFE) Spends $300 Million on Exploring Possibility of Split http://www.google.ca/url?sa=t&rct=j&q=&esrc=s&sourc...
An intersting point of view for you all: May 22, 2015, 1:12 P.M. ET Esperion Therapeutics: 15 Reasons to Take Profit...
Was this what the Dr. was forseeing? Introducing PfizerKline: Analyst Makes New Case for Merger of GlaxoSmithKline (GSK...
Pfizer (PFE) to make a play on Shire plc ? http://www.nasdaq.com/article/could-this-dark-horse-be-pfizer-incs-next-majo...
Well here's another M&A rumor from SA regarding PFE... -According to Reuters, Pfizer (PFE +0.2%) is negotiating a tak...
For those of you either owning or considering big Pharma companies here is an article on Patent Expiration for you to co...
I promised those of you that asked I'd get back here and tell you what are the three stocks I have a bead on to buy with...
By October 3, 2013, the U.S. Food and Drug Administration (FDA) will decide whether to approve Ligand Pharmaceutical's (...
Entfor drips there is pfizer pfe its a guarenteed winner thouh not in the near future w// the money they have and experi...